Rainbow Children's Medicare Approves FY26 Results, Reappoints Key Directors, Declares Dividend
Rainbow Children's Medicare approved FY26 results and recommended a final dividend of ₹3.5 per share. The 28th AGM is on July 29, 2026, with July 21, 2026, as the record date. Key directors Dr. Ramesh Kancharla, Dr. Dinesh Kumar Chirla, Mr. Santanu Mukherjee, and Ms. Sundari R. Pisupati were re-appointed for five-year terms.
The re-appointment of key directors and the declaration of dividend are positive developments that can impact investor confidence and the company's governance structure.
The company reported its financial results, recommended a dividend, and re-appointed key management personnel, indicating stability and continuity.
Rainbow Children's Medicare Limited announced the outcome of its Board Meeting held on May 23, 2026. The Board approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, along with the unmodified audit reports from S.R. Batliboi & Associates LLP.
The Board recommended a final dividend of ₹ 3.5 per Equity Share (35%) for the Financial Year 2025-26, subject to shareholder approval at the upcoming 28th Annual General Meeting (AGM). The dividend will be dispatched/credited within 30 days from the conclusion of the AGM.
The 28th AGM is scheduled to be convened on Wednesday, July 29, 2026, through Video Conferencing / Other Audio-Visual Means. Tuesday, July 21, 2026, has been fixed as the Record Date for the payment of the Final Dividend and for the purpose of the AGM.
Furthermore, the Board approved the re-appointment of Dr. Ramesh Kancharla as Chairman and Managing Director for a term of five years from August 11, 2026, to August 10, 2031. Dr. Dinesh Kumar Chirla was re-appointed as Whole Time Director for a similar five-year term. Mr. Santanu Mukherjee was re-appointed as Independent Director for a second term of five years from October 22, 2026, to October 21, 2031. Ms. Sundari R. Pisupati was also re-appointed as Independent Director for a second term of five years from September 16, 2026, to September 15, 2031. All re-appointments are subject to shareholder approval at the ensuing AGM.
Additionally, M/s. Lavanya & Associates LLP were re-appointed as the Cost Auditors for the Financial Year 2026-27. The Board Meeting commenced at 4:45 PM and concluded at 6:30 PM.
What to do with a filing like this
Rainbow Childrens Medicare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Rainbow Childrens Medicare Limited. Read the original for the full detail.